Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemarituzumab + pembrolizumab + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
A combination regimen consisting of **bemarituzumab** (a monoclonal antibody targeting fibroblast growth factor receptor 2b), **pembrolizumab** (an anti-PD-1 immune checkpoint inhibitor), **carboplatin** (a platinum-based chemotherapeutic agent), and **paclitaxel** (a microtubule inhibitor). This treatment protocol is designed for use in advanced solid tumors—most notably studied in non-small cell lung cancer (NSCLC) and head and neck cancers—and leverages multiple mechanisms of antitumor activity: bemarituzumab blocks fibroblast growth factor signaling pathways involved in tumor proliferation; pembrolizumab activates immune-mediated tumor destruction by inhibiting the PD-1/PD-L1 immune checkpoint; carboplatin and paclitaxel disrupt tumor cell division and trigger cell death[4][1][2].
- Brand names
- generic carboplatingeneric paclitaxel
- Other names
- bemarituzumab + pembrolizumab + carboplatin + paclitaxel
02
Targets
N7-G (DNA guanine-N7 adduct)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)
Beyond the preview
Go deeper on bemarituzumab + pembrolizumab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemarituzumab + pembrolizumab + carboplatin + paclitaxel.